Targeting vascular niche by parathyroid hormone

Caterina Pagliarulo, Paola Salvatore, Claudio Napoli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Currently, the parathyroid hormone (PTH) is a drug approved for use in humans only in bone metabolism diseases, as the osteoporosis. The PTH acts primarily by binding to its principal receptor, PTH/PTHrP-R, a member of the class B G protein-coupled receptor (GPCR) family that includes together receptors for other therapeutically important peptide hormones. PTH plays a central role in the maintenance of calcium and phosphate homeostasis and bone health. It acts to maintain bone and mineral homeostasis through several mechanisms: elevation of blood calcium by increasing osteoclastic bone resorption; enhancement of renal calcium reabsorption; stimulation of renal 1,25-dihydroxyvitamin D synthesis, leading to increased intestinal calcium absorption; and promotion of phosphaturia via inhibition of renal tubular transepithelial phosphate reabsorption. However, many findings indicate that the PTH could be a future drug essential in therapy of cardiovascular diseases through multiple effects on hematopoietic stem cells niche. In adult bone marrow, the hamatopoietic stem cells are located in the trabecular endosteum (osteoblastic niche) or sinusoidal perivascular areas (vascular niche). A plausible function for the vascular niche is to assist hematopoietic stem cells in transendothelial migration, which is important during both homing and mobilization. Indeed, in experimental models, PTH treatment increases migration of angiogenic CD45+/CD34+ progenitor cells to the hindlimb ischemia as well as in the ischemic heart, promoting tissue repair by enhanced neovascularization and cell survival.

Original languageEnglish
Pages (from-to)2984-2990
Number of pages7
JournalCurrent Medicinal Chemistry
Volume15
Issue number28
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Parathyroid Hormone
Blood Vessels
Bone
Stem cells
Hematopoietic Stem Cells
Calcium
Homeostasis
Stem Cells
Familial Hypophosphatemia
Parathyroid Hormone Receptor Type 1
Essential Drugs
Stem Cell Niche
Transendothelial and Transepithelial Migration
Kidney
Parathyroid Hormone-Related Protein
Bone and Bones
Peptide Hormones
Bone Diseases
Intestinal Absorption
Hindlimb

Keywords

  • Cardiovascular diseases
  • Hematopoietic stem cells
  • Hindlimb ischemia
  • Osteoporosis
  • Parathyroid Hormone
  • Peptide hormones
  • Phosphate homeostasis
  • Vascular Niche

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Targeting vascular niche by parathyroid hormone. / Pagliarulo, Caterina; Salvatore, Paola; Napoli, Claudio.

In: Current Medicinal Chemistry, Vol. 15, No. 28, 12.2008, p. 2984-2990.

Research output: Contribution to journalArticle

Pagliarulo, Caterina ; Salvatore, Paola ; Napoli, Claudio. / Targeting vascular niche by parathyroid hormone. In: Current Medicinal Chemistry. 2008 ; Vol. 15, No. 28. pp. 2984-2990.
@article{5a4823cb19824e109e7a47182d17bb71,
title = "Targeting vascular niche by parathyroid hormone",
abstract = "Currently, the parathyroid hormone (PTH) is a drug approved for use in humans only in bone metabolism diseases, as the osteoporosis. The PTH acts primarily by binding to its principal receptor, PTH/PTHrP-R, a member of the class B G protein-coupled receptor (GPCR) family that includes together receptors for other therapeutically important peptide hormones. PTH plays a central role in the maintenance of calcium and phosphate homeostasis and bone health. It acts to maintain bone and mineral homeostasis through several mechanisms: elevation of blood calcium by increasing osteoclastic bone resorption; enhancement of renal calcium reabsorption; stimulation of renal 1,25-dihydroxyvitamin D synthesis, leading to increased intestinal calcium absorption; and promotion of phosphaturia via inhibition of renal tubular transepithelial phosphate reabsorption. However, many findings indicate that the PTH could be a future drug essential in therapy of cardiovascular diseases through multiple effects on hematopoietic stem cells niche. In adult bone marrow, the hamatopoietic stem cells are located in the trabecular endosteum (osteoblastic niche) or sinusoidal perivascular areas (vascular niche). A plausible function for the vascular niche is to assist hematopoietic stem cells in transendothelial migration, which is important during both homing and mobilization. Indeed, in experimental models, PTH treatment increases migration of angiogenic CD45+/CD34+ progenitor cells to the hindlimb ischemia as well as in the ischemic heart, promoting tissue repair by enhanced neovascularization and cell survival.",
keywords = "Cardiovascular diseases, Hematopoietic stem cells, Hindlimb ischemia, Osteoporosis, Parathyroid Hormone, Peptide hormones, Phosphate homeostasis, Vascular Niche",
author = "Caterina Pagliarulo and Paola Salvatore and Claudio Napoli",
year = "2008",
month = "12",
doi = "10.2174/092986708786848695",
language = "English",
volume = "15",
pages = "2984--2990",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "28",

}

TY - JOUR

T1 - Targeting vascular niche by parathyroid hormone

AU - Pagliarulo, Caterina

AU - Salvatore, Paola

AU - Napoli, Claudio

PY - 2008/12

Y1 - 2008/12

N2 - Currently, the parathyroid hormone (PTH) is a drug approved for use in humans only in bone metabolism diseases, as the osteoporosis. The PTH acts primarily by binding to its principal receptor, PTH/PTHrP-R, a member of the class B G protein-coupled receptor (GPCR) family that includes together receptors for other therapeutically important peptide hormones. PTH plays a central role in the maintenance of calcium and phosphate homeostasis and bone health. It acts to maintain bone and mineral homeostasis through several mechanisms: elevation of blood calcium by increasing osteoclastic bone resorption; enhancement of renal calcium reabsorption; stimulation of renal 1,25-dihydroxyvitamin D synthesis, leading to increased intestinal calcium absorption; and promotion of phosphaturia via inhibition of renal tubular transepithelial phosphate reabsorption. However, many findings indicate that the PTH could be a future drug essential in therapy of cardiovascular diseases through multiple effects on hematopoietic stem cells niche. In adult bone marrow, the hamatopoietic stem cells are located in the trabecular endosteum (osteoblastic niche) or sinusoidal perivascular areas (vascular niche). A plausible function for the vascular niche is to assist hematopoietic stem cells in transendothelial migration, which is important during both homing and mobilization. Indeed, in experimental models, PTH treatment increases migration of angiogenic CD45+/CD34+ progenitor cells to the hindlimb ischemia as well as in the ischemic heart, promoting tissue repair by enhanced neovascularization and cell survival.

AB - Currently, the parathyroid hormone (PTH) is a drug approved for use in humans only in bone metabolism diseases, as the osteoporosis. The PTH acts primarily by binding to its principal receptor, PTH/PTHrP-R, a member of the class B G protein-coupled receptor (GPCR) family that includes together receptors for other therapeutically important peptide hormones. PTH plays a central role in the maintenance of calcium and phosphate homeostasis and bone health. It acts to maintain bone and mineral homeostasis through several mechanisms: elevation of blood calcium by increasing osteoclastic bone resorption; enhancement of renal calcium reabsorption; stimulation of renal 1,25-dihydroxyvitamin D synthesis, leading to increased intestinal calcium absorption; and promotion of phosphaturia via inhibition of renal tubular transepithelial phosphate reabsorption. However, many findings indicate that the PTH could be a future drug essential in therapy of cardiovascular diseases through multiple effects on hematopoietic stem cells niche. In adult bone marrow, the hamatopoietic stem cells are located in the trabecular endosteum (osteoblastic niche) or sinusoidal perivascular areas (vascular niche). A plausible function for the vascular niche is to assist hematopoietic stem cells in transendothelial migration, which is important during both homing and mobilization. Indeed, in experimental models, PTH treatment increases migration of angiogenic CD45+/CD34+ progenitor cells to the hindlimb ischemia as well as in the ischemic heart, promoting tissue repair by enhanced neovascularization and cell survival.

KW - Cardiovascular diseases

KW - Hematopoietic stem cells

KW - Hindlimb ischemia

KW - Osteoporosis

KW - Parathyroid Hormone

KW - Peptide hormones

KW - Phosphate homeostasis

KW - Vascular Niche

UR - http://www.scopus.com/inward/record.url?scp=58149402893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149402893&partnerID=8YFLogxK

U2 - 10.2174/092986708786848695

DO - 10.2174/092986708786848695

M3 - Article

C2 - 19075646

AN - SCOPUS:58149402893

VL - 15

SP - 2984

EP - 2990

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 28

ER -